Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EGRX NASDAQ:EPRX NASDAQ:IPHA NASDAQ:MDWD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEGRXEagle Pharmaceuticals$3.37+10.1%$3.34$1.50▼$3.87$23.38M0.836,074 shs1,564 shsEPRXEupraxia Pharmaceuticals$5.96-1.3%$5.36$2.20▼$6.31$214.33M1.4920,385 shs37,872 shsIPHAInnate Pharma$1.87-3.6%$2.06$1.29▼$3.51$172.38M0.2214,856 shs12,205 shsMDWDMediWound$16.98-1.6%$18.27$14.14▼$22.50$183.52M0.25152,918 shs97,848 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEGRXEagle Pharmaceuticals+10.13%+4.98%+5.64%+17.22%-21.26%EPRXEupraxia Pharmaceuticals-1.32%+11.82%+12.45%+37.96%+110.60%IPHAInnate Pharma-3.61%-6.50%-15.96%+3.89%-16.89%MDWDMediWound-1.57%-4.82%-2.64%-11.05%-3.36%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEGRXEagle Pharmaceuticals$3.37+10.1%$3.34$1.50▼$3.87$23.38M0.836,074 shs1,564 shsEPRXEupraxia Pharmaceuticals$5.96-1.3%$5.36$2.20▼$6.31$214.33M1.4920,385 shs37,872 shsIPHAInnate Pharma$1.87-3.6%$2.06$1.29▼$3.51$172.38M0.2214,856 shs12,205 shsMDWDMediWound$16.98-1.6%$18.27$14.14▼$22.50$183.52M0.25152,918 shs97,848 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEGRXEagle Pharmaceuticals+10.13%+4.98%+5.64%+17.22%-21.26%EPRXEupraxia Pharmaceuticals-1.32%+11.82%+12.45%+37.96%+110.60%IPHAInnate Pharma-3.61%-6.50%-15.96%+3.89%-16.89%MDWDMediWound-1.57%-4.82%-2.64%-11.05%-3.36%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEGRXEagle Pharmaceuticals 0.00N/AN/AN/AEPRXEupraxia Pharmaceuticals 3.17Buy$11.0084.56% UpsideIPHAInnate Pharma 2.25Hold$6.50247.59% UpsideMDWDMediWound 2.80Moderate Buy$32.2589.93% UpsideCurrent Analyst Ratings BreakdownLatest EGRX, MDWD, IPHA, and EPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/18/2025IPHAInnate PharmaLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/18/2025IPHAInnate PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral9/18/2025IPHAInnate PharmaLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$10.00 ➝ $2.008/20/2025EPRXEupraxia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.008/19/2025MDWDMediWoundZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/28/2025IPHAInnate PharmaBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy7/24/2025EPRXEupraxia PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$11.006/26/2025EPRXEupraxia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.006/26/2025EPRXEupraxia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.00(Data available from 9/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEGRXEagle Pharmaceuticals$257.55M0.17$8.43 per share0.40N/A∞EPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AN/AIPHAInnate Pharma$21.77M7.92N/AN/A$0.11 per share17.00MDWDMediWound$19.86M9.24N/AN/A$2.89 per share5.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEGRXEagle Pharmaceuticals$35.64MN/A0.00∞N/AN/AN/AN/AN/AEPRXEupraxia Pharmaceuticals-$25.50M-$0.85N/AN/AN/AN/A-626.84%-118.31%11/6/2025 (Estimated)IPHAInnate Pharma-$53.53MN/A0.00∞N/AN/AN/AN/AN/AMDWDMediWound-$30.22M-$2.64N/AN/AN/A-142.18%-96.71%-39.73%11/25/2025 (Estimated)Latest EGRX, MDWD, IPHA, and EPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025MDWDMediWound-$0.55-$1.23-$0.68-$1.23$5.68 million$5.71 million8/12/2025Q2 2025EPRXEupraxia Pharmaceuticals-$0.21-$0.26-$0.05-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AIPHAInnate PharmaN/AN/AN/AN/AN/AMDWDMediWoundN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEGRXEagle PharmaceuticalsN/AN/AN/AEPRXEupraxia PharmaceuticalsN/A8.728.72IPHAInnate Pharma3.522.212.60MDWDMediWoundN/A1.481.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEGRXEagle Pharmaceuticals85.36%EPRXEupraxia PharmaceuticalsN/AIPHAInnate Pharma0.16%MDWDMediWound46.83%Insider OwnershipCompanyInsider OwnershipEGRXEagle Pharmaceuticals28.90%EPRXEupraxia PharmaceuticalsN/AIPHAInnate Pharma31.89%MDWDMediWound9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataEPRXEupraxia Pharmaceuticals2935.96 millionN/AN/AIPHAInnate Pharma22092.18 million62.79 millionNot OptionableMDWDMediWound8010.81 million9.81 millionOptionableEGRX, MDWD, IPHA, and EPRX HeadlinesRecent News About These CompaniesMediWound Ltd. (NASDAQ:MDWD) Receives $32.25 Consensus Price Target from BrokeragesSeptember 20 at 2:57 AM | americanbankingnews.comSilverberg Bernstein Capital Management LLC Buys 43,591 Shares of MediWound Ltd. $MDWDSeptember 17 at 6:13 AM | marketbeat.comMediWound Ltd. (NASDAQ:MDWD) Given Consensus Recommendation of "Moderate Buy" by BrokeragesSeptember 16, 2025 | marketbeat.comMediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association CongressSeptember 2, 2025 | markets.businessinsider.comMediWound's NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association CongressSeptember 2, 2025 | globenewswire.comMediWound Is A Buy Opportunity On The DipSeptember 2, 2025 | seekingalpha.comMediWound (NASDAQ:MDWD) Downgraded to "Hold" Rating by Zacks ResearchAugust 23, 2025 | marketbeat.comMediWound to Present at the H.C. Wainwright 27th Annual Global ...August 22, 2025 | morningstar.comMMediWound to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceAugust 20, 2025 | globenewswire.comMediWound Executives Purchase Shares, Signaling ConfidenceAugust 19, 2025 | msn.comCraig-Hallum Sticks to Their Buy Rating for Mediwound (MDWD)August 17, 2025 | theglobeandmail.comAnalysts Have Made A Financial Statement On MediWound Ltd.'s (NASDAQ:MDWD) Second-Quarter ReportAugust 17, 2025 | finance.yahoo.comMediWound reports Q2 EPS ($1.23), consensus (57c)August 14, 2025 | msn.comMediWound Revenue Jumps 43% in Q2August 14, 2025 | aol.comAMediWound Reports Q2 2025 Financial Results and Strategic UpdatesAugust 14, 2025 | msn.comMediWound Ltd. (MDWD) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | seekingalpha.comMediWound (MDWD) Reports Q2 Loss, Beats Revenue EstimatesAugust 14, 2025 | zacks.comMediWound Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 14, 2025 | globenewswire.comMediWound Q2 2025 Earnings PreviewAugust 13, 2025 | msn.comMediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg UlcersAugust 13, 2025 | globenewswire.comMediWound Ltd. to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 14August 4, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEGRX, MDWD, IPHA, and EPRX Company DescriptionsEagle Pharmaceuticals NASDAQ:EGRX$3.37 +0.31 (+10.13%) As of 09/19/2025 02:58 PM EasternEagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.Eupraxia Pharmaceuticals NASDAQ:EPRX$5.96 -0.08 (-1.32%) Closing price 09/19/2025 03:59 PM EasternExtended Trading$6.19 +0.23 (+3.93%) As of 09/19/2025 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.Innate Pharma NASDAQ:IPHA$1.87 -0.07 (-3.61%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$1.88 +0.01 (+0.48%) As of 09/19/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.MediWound NASDAQ:MDWD$16.98 -0.27 (-1.57%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$16.96 -0.02 (-0.09%) As of 09/19/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Berkshire-Backed Lennar Slides After Weak Q3 Earnings Azure Leads While AI Excitement Fuels Microsoft Stock Caterpillar Stock Hits All-Time High—Is There More Room to Run? The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity McDonald’s: New All-Time Highs Are Inevitable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
